Senti Biosciences (SNTI) appoints Feng Hsiung to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- Wall St futures fall as chip stocks resume slide after Micron-led rally
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
Senti Bio Appoints Feng Hsiung to Board of Directors
March 13, 2025 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (Senti Bio, or the Company), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the Board).
We are pleased to welcome Feng to our Boardhe brings deep expertise in investment strategy and capital markets across multiple industries, said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. We look... More
